HLB announced that the FDA's manufacturing site issue for its liver cancer drug was resolved with a 'Voluntary Action Indicated' (VAI) classification, causing a 30% stock price surge.
Korean translation
HLB는 간암 신약 제조시설 이슈가 FDA로부터 '자발적 개선 필요(VAI)' 등급을 받아 해소되었다고 발표하였으며, 주가가 약 30% 급등함.